Literature DB >> 3232185

Albendazole treatment of human cystic echinococcosis.

T Todorov1, K Vutova, D Petkov, G Mechkov, K Kolev.   

Abstract

The effect of albendazole was investigated in 20 patients with single or multiorgan hydatid cyst disease. Albendazole was used at a dose of 10 mg/kg daily in cycles of 28 d for four cycles with 15 d between cycles. Follow-up ranged from 12-18 months. Response varied according to the organ involved, the most successful results being with liver and peritoneal cysts. A positive response was seen in 47% of 34 cyst sites and a partial response was seen in a further 38% of sites. Overall response was classed as completely successful in 30% of patients, and partially successful in 60% at the end of follow-up. Adverse events were rare, although occasional abnormalities of liver function were seen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3232185     DOI: 10.1016/0035-9203(88)90161-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  7 in total

1.  High mebendazole doses in pulmonary and hepatic hydatid disease.

Authors:  J Messaritakis; P Psychou; P Nicolaidou; T Karpathios; B Syriopoulou; A Fretzayas; F Krikos; N Matsaniotis
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

2.  Concentrations of albendazole in serum, cerebrospinal fluid and hydatidous brain cyst.

Authors:  D Moskopp; E Lotterer
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

Review 3.  Diagnosis and treatment of human hydatidosis.

Authors:  H Wen; R R New; P S Craig
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

4.  Factors influencing the response to chemotherapy in human cystic echinococcosis.

Authors:  T Todorov; G Mechkov; K Vutova; P Georgiev; I Lazarova; Z Tonchev; G Nedelkov
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

5.  Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Authors:  Mar Siles-Lucas; Adriano Casulli; Roberto Cirilli; David Carmena
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

6.  Experience in the chemotherapy of severe, inoperable echinococcosis in man.

Authors:  T Todorov; K Vutova; G Mechkov; Z Tonchev; P Georgiev; I Lazarova
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

7.  Albendazole in the treatment of pulmonary echinococcosis.

Authors:  P Aggarwal; J P Wali
Journal:  Thorax       Date:  1991-08       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.